These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 9516968

  • 1. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S.
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [Abstract] [Full Text] [Related]

  • 2. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 4. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 15; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 6. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 7. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K.
    Cancer; 1996 Aug 01; 78(3):487-92. PubMed ID: 8697395
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR.
    Cancer Res; 1994 Jun 01; 54(11):2900-7. PubMed ID: 8187075
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.
    Br J Cancer; 1999 Mar 01; 79(7-8):1190-8. PubMed ID: 10098758
    [Abstract] [Full Text] [Related]

  • 11. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 01; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 12. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N, Thomssen C.
    Zentralbl Gynakol; 2003 Sep 01; 125(9):362-7. PubMed ID: 14569518
    [Abstract] [Full Text] [Related]

  • 13. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
    Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB.
    Cancer Res; 1994 Aug 01; 54(15):4065-71. PubMed ID: 8033138
    [Abstract] [Full Text] [Related]

  • 14. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H.
    Cancer; 2006 Mar 01; 106(5):1026-35. PubMed ID: 16435385
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J.
    Clin Cancer Res; 1998 Jan 01; 4(1):189-96. PubMed ID: 9516970
    [Abstract] [Full Text] [Related]

  • 16. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
    Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD.
    Cancer Res; 1995 Apr 01; 55(7):1423-7. PubMed ID: 7882345
    [Abstract] [Full Text] [Related]

  • 17. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
    Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M.
    Cancer Res; 2003 Jan 15; 63(2):337-41. PubMed ID: 12543785
    [Abstract] [Full Text] [Related]

  • 18. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007 Jan 15; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 15; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 15; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.